Judah Frommer
Stock Analyst at Morgan Stanley
(4.09)
# 494
Out of 5,152 analysts
183
Total ratings
61.43%
Success rate
8.7%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Maintains: Overweight | $191 → $201 | $172.57 | +16.47% | 2 | Mar 3, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $28 | $14.21 | +97.04% | 1 | Mar 3, 2026 | |
| GMAB Genmab | Reinstates: Equal-Weight | $34 | $27.48 | +23.73% | 1 | Feb 16, 2026 | |
| RGNX REGENXBIO | Maintains: Overweight | $25 → $18 | $8.72 | +106.42% | 3 | Feb 10, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $112.70 | +28.66% | 4 | Jan 9, 2026 | |
| ZBIO Zenas BioPharma | Downgrades: Equal-Weight | $37 → $19 | $25.26 | -24.78% | 2 | Jan 6, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $25.09 | +43.48% | 1 | Dec 1, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $13.08 | +45.26% | 2 | Nov 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $20.15 | +29.03% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $29.36 | +46.46% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $31 → $22 | $33.38 | -34.09% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $6 | $8.64 | -30.56% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $81 → $106 | $114.36 | -7.31% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $18.50 | +89.19% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.35 | +27.66% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.37 | +2,819.71% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $3.34 | +289.22% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $34.65 | -33.62% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $63.33 | -21.05% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $16.23 | +768.76% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $3.54 | +154.24% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $30.14 | -27.01% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $4.85 | +44.33% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $8.16 | -1.96% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $70.66 | -34.90% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.77 | +152.71% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $10.65 | +416.43% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $143.57 | -67.96% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $90.04 | -45.58% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $982.57 | -62.34% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $92.15 | -66.36% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $85.78 | -11.40% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $146.55 | +24.19% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $115.91 | -7.69% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $109.23 | -13.03% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.30 | +4.05% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $221.65 | -47.67% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $98.47 | -61.41% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $76.91 | -71.40% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $71.57 | -51.10% | 9 | Apr 29, 2020 |
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $191 → $201
Current: $172.57
Upside: +16.47%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $28
Current: $14.21
Upside: +97.04%
Genmab
Feb 16, 2026
Reinstates: Equal-Weight
Price Target: $34
Current: $27.48
Upside: +23.73%
REGENXBIO
Feb 10, 2026
Maintains: Overweight
Price Target: $25 → $18
Current: $8.72
Upside: +106.42%
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $112.70
Upside: +28.66%
Zenas BioPharma
Jan 6, 2026
Downgrades: Equal-Weight
Price Target: $37 → $19
Current: $25.26
Upside: -24.78%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $25.09
Upside: +43.48%
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $13.08
Upside: +45.26%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $20.15
Upside: +29.03%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $29.36
Upside: +46.46%
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $33.38
Upside: -34.09%
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $8.64
Upside: -30.56%
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $114.36
Upside: -7.31%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $18.50
Upside: +89.19%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.35
Upside: +27.66%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.37
Upside: +2,819.71%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $3.34
Upside: +289.22%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $34.65
Upside: -33.62%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $63.33
Upside: -21.05%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $16.23
Upside: +768.76%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $3.54
Upside: +154.24%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $30.14
Upside: -27.01%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $4.85
Upside: +44.33%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $8.16
Upside: -1.96%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $70.66
Upside: -34.90%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.77
Upside: +152.71%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $10.65
Upside: +416.43%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $143.57
Upside: -67.96%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $90.04
Upside: -45.58%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $982.57
Upside: -62.34%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $92.15
Upside: -66.36%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $85.78
Upside: -11.40%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $146.55
Upside: +24.19%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $115.91
Upside: -7.69%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $109.23
Upside: -13.03%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.30
Upside: +4.05%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $221.65
Upside: -47.67%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $98.47
Upside: -61.41%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $76.91
Upside: -71.40%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $71.57
Upside: -51.10%